Edwards Lifesciences price target raised to $95 from $90 at Piper Sandler

Piper Sandler analyst Adam Maeder raised the firm’s price target on Edwards Lifesciences (EW) to $95 from $90 and keeps an Overweight rating on the shares. The firm notes the company reported robust Q3 results this evening, posting beats across the board. Given the Q3 results and year-to-date performance, Edwards increased its FY 2025 top-line guidance to the higher end of its previously guided +9%-10% ex-FX year-over-year and its adjusted EPS guidance to $2.56-$2.62.